미국의 생물학적 지표 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 방법별, 최종 용도별 및 부문별 예측(2026-2033년)

U.S. Biological Indicators Market Summary

The U.S. biological indicators market size was estimated at USD 214.15 million in 2025 and is projected to reach USD 334.96 million by 2033, growing at a CAGR of 5.87% from 2026 to 2033. The market is primarily driven by the growing emphasis on sterilization validation and infection control across the healthcare and life sciences industries.

Increasing volumes of surgical procedures and hospital-acquired infection (HAI) prevention initiatives are pushing hospitals, pharmaceutical manufacturers, and medical device companies to adopt reliable sterilization monitoring solutions. Strict regulatory requirements from organizations such as the U.S. Food and Drug Administration and the Centers for Disease Control and Prevention mandate routine monitoring of sterilization processes using biological indicators to ensure their effectiveness in hospitals, laboratories, and pharmaceutical manufacturing facilities.

The U.S. biological indicators industry is driven by rising surgical procedure volumes and the growing emphasis on effective sterilization monitoring across healthcare facilities. As surgical procedures continue to grow in hospitals, ambulatory surgical centers, and specialty clinics, the need to ensure proper sterilization of surgical instruments becomes critical to prevent healthcare-associated infections (HAIs) and maintain patient safety. Biological indicators play a key role in validating sterilization processes such as steam, ethylene oxide, and hydrogen peroxide, ensuring that sterilization cycles effectively eliminate microbial contaminants.

In addition, the growth in elective cosmetic surgeries is further increasing the frequency of sterilization cycles. According to the 2024 Plastic Surgery Statistics Report published by the American Society of Plastic Surgeons, breast augmentation procedures increased from 304,181 in 2023 to 306,196 in 2024, reflecting a 1% year-on-year rise. This increasing surgical throughput is expected to drive the routine adoption of biological indicators as part of standard sterilization monitoring practices in the U.S. healthcare system.

The growth of the U.S. biological indicators industry is supported by rising investments in pharmaceutical and medical device manufacturing nationwide. Several companies are expanding their production capabilities to meet rising domestic demand and comply with stringent regulatory standards for sterile manufacturing. For instance, in April 2025, BDR Pharmaceuticals announced plans to expand its U.S. operations through the acquisition of manufacturing facilities, supported by an investment of USD 100 million.

Similarly, in June 2025, UCB revealed plans to establish a new biologics manufacturing facility in the U.S., with an estimated economic impact of approximately USD 5 billion. Such investments are increasing the need for validated sterilization processes within pharmaceutical and medical device production. Biological indicators play a critical role in confirming the effectiveness of sterilization for products such as injectable drugs, vials, and syringes in pharmaceutical manufacturing, as well as for implantable medical devices, including pacemakers, stents, and orthopedic implants. As a result, the expansion of sterile manufacturing infrastructure in the U.S. is expected to drive consistent demand for biological indicators used in sterilization monitoring.

The increasing availability of advanced automated sterilization monitoring technologies is expected to support the growth of the U.S. biological indicators industry. Healthcare facilities, particularly sterile processing departments (SPDs), are under growing pressure to improve operational efficiency while maintaining strict compliance with regulatory sterilization standards. As a result, many hospitals and healthcare systems are adopting automated solutions that reduce manual, time-consuming monitoring procedures and enhance workflow efficiency. Industry players are introducing innovative systems that enable faster and more reliable sterilization verification.

For instance, the STERRAD VELOCITY BI/PCD System developed by Advanced Sterilization Products offers one of the fastest biological indicator readout times of approximately 15 minutes. The system integrates automated features that streamline several stages of the monitoring process, including guided biological indicator processing, automatic generation of audit-ready documentation, storage of up to 22,000 BI results, and correlation of sterilizer loads with monitoring data. Such rapid and automated processing can reduce instrument quarantine times by up to 38%, enabling faster turnaround of sterilized instruments and supporting improved sterilization workflow management in U.S. healthcare facilities.

U.S. Biological Indicators Market Report Segmentation

This report forecasts revenue growth at the country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. biological indicators market report based on the product, method, and end use:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Self-Contained (Vials/Ampoules)
• Strips
• Cards / Rapid Readout BIs
• Others
• Method Outlook (Revenue, USD Million, 2021 - 2033)
• Steam Sterilization
• Ethylene Oxide Sterilization
• Hydrogen Peroxide Sterilization
• Irradiation Sterilization (Gamma, E-beam)
• Dry Heat Sterilization
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals & Clinics (CSSD / Infection Control Units)
• Ambulatory Surgery Centers (ASCs) & Dental Clinics
• Biopharma & Biotech Companies
• Medical Device Manufacturers
• Contract Sterilization Service Providers
• Research & Academic Institutes
• Other End Uses

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Research Methodology
• 1.3. Information Procurement
• 1.4. Purchased database.
• 1.5. GVR's internal database
• 1.6. Secondary sources
• 1.7. Third Party Perspective
• 1.8. Primary research
• 1.9. Details of primary research
• 1.10. Information or Data Analysis
• 1.11. Data analysis models
• 1.12. Market Formulation & Validation
• 1.13. Model Details
• 1.14. Commodity flow analysis (Model 1)
  • 1.14.1. Approach 1: Commodity flow approach
• 1.15. Volume price analysis (Model 2)
  • 1.15.1. Approach 2: Volume price analysis
• 1.16. List of Secondary Sources
• 1.17. List of Primary Sources
• 1.18. List of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Biological Indicators Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing Prevalence of Healthcare-Associated Infections (HAIs)
    • 3.2.1.2. Stringent Regulatory Requirements and Standards
    • 3.2.1.3. Growth in Surgical Procedures and Healthcare Infrastructure
    • 3.2.1.4. Technological Innovation
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High Cost of Advanced Indicators and Supporting Systems
  • 3.2.3. Market Opportunities Analysis
    • 3.2.3.1. Integration with Digital/IoT & Automation
    • 3.2.3.2. Emerging Market Expansion
  • 3.2.4. Market Challenges Analysis
    • 3.2.4.1. Competition from Alternative & Less Expensive Technologies
• 3.3. Biological Indicators Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining Power of Suppliers
    • 3.3.1.2. Bargaining Power of Buyers
    • 3.3.1.3. Threat of Substitutes
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political & Legal Landscape
    • 3.3.2.2. Economic and Social Landscape
    • 3.3.2.3. Technological Landscape

Chapter 4. U.S. Biological Indicators Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. U.S. Biological Indicators Market: Product Movement Analysis & Market Share, 2025 & 2033
• 4.3. Self-Contained
  • 4.3.1. Self-Contained Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.4. Strips
  • 4.4.1. Strips Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Cards / Rapid Readout BIs
  • 4.5.1. Cards / Rapid Readout BIs Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Others
  • 4.6.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Biological Indicators Market: Method Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. U.S. Biological Indicators Market: Method Movement Analysis & Market Share, 2025 & 2033
• 5.3. Steam Sterilization
  • 5.3.1. Steam Sterilization Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.4. Ethylene Oxide Sterilization
  • 5.4.1. Ethylene Oxide Sterilization Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Hydrogen Peroxide Sterilization
  • 5.5.1. Hydrogen Peroxide Sterilization Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Irradiation Sterilization
  • 5.6.1. Irradiation Sterilization Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Dry Heat Sterilization
  • 5.7.1. Dry Heat Sterilization Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Biological Indicators Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. U.S. Biological Indicators Market: End Use Movement Analysis & Market Share, 2025 & 2033
• 6.3. Hospitals & Clinics
  • 6.3.1. Hospitals & Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.4. Ambulatory Surgery Centers (ASCs) & Dental Clinics
  • 6.4.1. Ambulatory Surgery Centers (ASCs) & Dental Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Biopharma & Biotech Companies
  • 6.5.1. Biopharma & Biotech Companies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Medical Device Manufacturers
  • 6.6.1. Medical Device Manufacturers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Contract Sterilization Service Providers
  • 6.7.1. Contract Sterilization Service Providers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.8. Research & Academic Institutes
  • 6.8.1. Research & Academic Institutes Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.9. Other End Uses
  • 6.9.1. Other End Uses Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Market Participant Categorization
• 7.2. Key Company Profiles
  • 7.2.1. STERIS
    • 7.2.1.1. Company Overview
    • 7.2.1.2. Financial Performance
    • 7.2.1.3. Product Benchmarking
    • 7.2.1.4. Strategic Initiatives
  • 7.2.2. Solventum (3M Health Care)
    • 7.2.2.1. Company Overview
    • 7.2.2.2. Financial Performance
    • 7.2.2.3. Product Benchmarking
    • 7.2.2.4. Strategic Initiatives
  • 7.2.3. Getinge
    • 7.2.3.1. Company Overview
    • 7.2.3.2. Financial Performance
    • 7.2.3.3. Product Benchmarking
    • 7.2.3.4. Strategic Initiatives
  • 7.2.4. Mesa Laboratories, Inc.
    • 7.2.4.1. Company Overview
    • 7.2.4.2. Financial Performance
    • 7.2.4.3. Product Benchmarking
    • 7.2.4.4. Strategic Initiatives
  • 7.2.5. Terragene S.A.
    • 7.2.5.1. Company Overview
    • 7.2.5.2. Financial Performance
    • 7.2.5.3. Product Benchmarking
    • 7.2.5.4. Strategic Initiatives
  • 7.2.6. Propper Manufacturing Co., Inc.
    • 7.2.6.1. Company Overview
    • 7.2.6.2. Financial Performance
    • 7.2.6.3. Product Benchmarking
    • 7.2.6.4. Strategic Initiatives
  • 7.2.7. Ecolab Inc.
    • 7.2.7.1. Company Overview
    • 7.2.7.2. Financial Performance
    • 7.2.7.3. Product Benchmarking
    • 7.2.7.4. Strategic Initiatives
  • 7.2.8. H.W.Andersen Products Ltd.
    • 7.2.8.1. Company Overview
    • 7.2.8.2. Financial Performance
    • 7.2.8.3. Product Benchmarking
    • 7.2.8.4. Strategic Initiatives
  • 7.2.9. Medline Industries, LP.
    • 7.2.9.1. Company Overview
    • 7.2.9.2. Financial Performance
    • 7.2.9.3. Product Benchmarking
    • 7.2.9.4. Strategic Initiatives
  • 7.2.10. True Indicating
    • 7.2.10.1. Company Overview
    • 7.2.10.2. Financial Performance
    • 7.2.10.3. Product Benchmarking
    • 7.2.10.4. Strategic Initiatives
  • 7.2.11. ASP (Fortive)
    • 7.2.11.1. Company Overview
    • 7.2.11.2. Financial Performance
    • 7.2.11.3. Product Benchmarking
    • 7.2.11.4. Strategic Initiatives
  • 7.2.12. Hu-Friedy
    • 7.2.12.1. Company Overview
    • 7.2.12.2. Financial Performance
    • 7.2.12.3. Product Benchmarking
    • 7.2.12.4. Strategic Initiatives
• 7.3. Company Market Share Analysis, 2025